Amgen's Profit Falls 7.4% as Drug Sales Shrink

Apr 23rd, 2009 - Wall Street Journal

Related content:

Amgen Inc.'s first-quarter net income fell 7.4% as product sales slumped, prompting the company to lower its revenue projection for the year.

"Our first-quarter sales were affected by the continued deterioration of the global economy, which has led to changes in patient and physician behavior," said Kevin Sharer, the company's chairman and chief executive.

Drug companies, like most everyone else, are suffering from weak economic conditions that market-research firm IMS Health Inc. said will likely cause the U.S. pharmaceutical market to shrink ...

Read the whole story on Wall Street Journal or try our Toolbar
Bookmark and Share
blog comments powered by Disqus

Related stories:

  • FDA approves Johnson & Johnson rheumatoid arthritis drug golimumab

    Apr 25th, 2009 - Los Angeles Times

    Johnson & Johnson won U.S. approval of a rheumatoid arthritis drug designed to be injected less often than its top-selling product, Remicade. The Food and Drug Administration on Friday announced its decision on the medicine, golimumab...

  • Amgen Investors Bet That Worst Is Over After Dismal 1Q

    Apr 24th, 2009 - Wall Street Journal

    NEW YORK (Dow Jones)--Amgen Inc. (AMGN) shares are showing resilience Friday, despite the biotech's miserable first-quarter sales performance, as investors bet that the situation can only get better with key catalysts emerging in coming months.

  • Samsung First-Quarter Earnings Beat Expectations

    Apr 24th, 2009 - BusinessWeek

    South Korea's Samsung Electronics has joined a group of information technology giants to report earnings that beat industry expectations. Samsung, the world's largest...

  • Amazon.com Profit Rises 24% as Online Sales Hold Up

    Apr 23rd, 2009 - Bloomberg

    April 23 (Bloomberg) -- Amazon.com Inc., the world’sbiggest Internet retailer, reported first-quarter sales andprofit that beat analysts’ estimates, bolstered by free shippingoffers and demand for the Kindle electronic-book reader.

  • RPT-UPDATE 1-IMS lowers global phamaceutical forecast for 2009

    Apr 22nd, 2009 - Reuters

    * IMS now sees global growth of 2.5-3.5 pct * Sees $750 bln 2009 sales, down from prior $820 bln view * US market to decline by 1-2 percent * China set to become 3rd largest market in 2011 NEW YORK...

More stories ...

Google Search: